Dharma Biomedical
Steven J Melnick Ph.D, M.D.
Mission Statement
Laboratory Services
R & D Activities
Management Team
Selected Bibliography
Contact Us

Chairman and Founder

Philadelphia Eagles WinCraft 8'' x 8'' Color Car Decal,Pittsburgh Steelers Black Five-Piece Twin Bedding Set,Cleveland Browns WinCraft 12" x 30" Premium Pennant Matthew Stafford Jerseys Sale Cincinnati Bengals Jerseys Cheap Calvin Johnson Jerseys Sale .Seattle Seahawks 6'' x 6'' Metallic Logo Decal,Men's San Francisco 49ers Nike Black Lockdown II Half-Zip Jacket,Seattle Seahawks Kam Chancellor Legion of Boom Bobblehead Barry Sanders Jerseys Sale Cincinnati Bengals Jerseys Cheap

Steven J Melnick, Ph.D., M.D. the Company majority owner serves as Chief of the Department of Pathology and Clinical Laboratories at Miami Children's Hospital since 1997. He joined the Department of Pathology in 1992 following his Residency training at Mount Sinai Medical Center in Miami Beach. He earned his B.Sc. degree in Physics (1977) and Ph.D. in Chemistry (1982) at McGill University and his Medical Degree at Queen's University (1987), Kingston, Ontario. His research experience with botanical medicine goes back to 1975 where worked with and studied under Dr. Bernard R. Grad at the Allen Memorial Institute at McGill University during his undergraduate and graduate studies. This experience was instrumental in establishing the research laboratory dedicated to ethnobotanical research at Miami Children's Hospital in 1999. The laboratory and accumulated intellectual property were transitioned into a private company; Dharma Biomedical in early 2006. His bibliography contains over 100 peer-reviewed publications and abstracts. He is a frequent invited lecturer in medical industry symposia and is currently the study chair for two pediatric clinical trials in development; one which involves the use of Turmeric as an adjuvant therapy in high-risk childhood cancer patients and the other which involves the use of a whey-protein derivative as an intervention in pediatric cancer patients at high risk for cachexia.

Return to Management Team Main Page